Compare CAC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | OMER |
|---|---|---|
| Founded | 1875 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.5M | 628.9M |
| IPO Year | 1997 | 2009 |
| Metric | CAC | OMER |
|---|---|---|
| Price | $45.29 | $10.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $47.33 | $27.50 |
| AVG Volume (30 Days) | 72.7K | ★ 1.7M |
| Earning Date | 01-27-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | ★ 9.13 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $215,172,000.00 | N/A |
| Revenue This Year | $44.50 | N/A |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | $12.94 | ★ N/A |
| Revenue Growth | ★ 27.50 | N/A |
| 52 Week Low | $34.53 | $2.95 |
| 52 Week High | $46.99 | $13.60 |
| Indicator | CAC | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 76.69 | 59.20 |
| Support Level | $41.38 | $9.31 |
| Resistance Level | $41.60 | $11.71 |
| Average True Range (ATR) | 1.14 | 0.67 |
| MACD | 0.39 | -0.01 |
| Stochastic Oscillator | 97.56 | 51.11 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.